Search research articles
Contact Us
Filters
Showing results (111-120 of 123) with videos related to
Page
of 13
Sort By:
Journal for Immunotherapy of Cancer
|
April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Tessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 6, 2020
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
The New England Journal of Medicine
|
April 20, 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 17, 2024
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Susan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Cancer Cell
|
September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Cancer Cell
|
December 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 123) with videos related to
Sort By:
Page
of 13
Journal for Immunotherapy of Cancer
|
April 21, 2021
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer
|
March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
Tessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 6, 2020
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 7, 2022
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
The New England Journal of Medicine
|
April 20, 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 17, 2024
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Susan M Swetter, Douglas Johnson, Mark R Albertini, et al.
Cancer Cell
|
September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Cancer Cell
|
December 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Page
of 13